Policy & Legislation
FDA Grants 510(k) Clearance for Trigeminal Nerve Ablation System to Treat Facial Pain
The FDA granted clearance to market the OneRF Trigeminal Nerve Ablation System (NeuroOne) for use in procedures to create radiofrequency (RF) lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures.
AUGUST 25, 2025
Tool Kit for Measuring Opioid Misuse Needs Expansion
The National Survey on Drug Use and Health has been a key metric for measuring drug use across the United States since 1971.
AUGUST 25, 2025
FDA Approves First Fibromyalgia Treatment in 15 Years
The FDA has approved Tonmya for the treatment of fibromyalgiac
AUGUST 19, 2025
FDA Approves Ketamine for Surgical Pain Management
THe FDA has approved a new ketamine product for surgical pain management.
AUGUST 13, 2025
Illinois Law Could Serve as Blueprint for Stronger Opioid Prescribing Protections
Illinois House Bill 5373—which amends the state’s Controlled Substances Act to offer more flexibility to prescribers in the use of opioids for chronic pain treatment—offers several benefits for doctors, primarily focused on chronic pain treatment and patient care.
AUGUST 8, 2025
FDA Updates Opioid Labeling Requirements to Reflect Long-Term Risks
The FDA announced major changes to its opioid pain medication labeling regulations that better emphasize and explain the risks of using the medications over long periods of time.
AUGUST 5, 2025
Access to Pain Medication a Major Issue for Philadelphia Clinics
Access to pain medications, like buprenorphine and methadone, remains a significant hurdle for many, with only one-fourth of the U.S. population with opioid use disorder receiving treatment for the condition.
JUNE 27, 2025
HALT Act Would Recategorize Fentanyl as a Schedule I Controlled Substance; Is That a Good Thing?
The Senate HALT of Fentanyl Act attempts to address the drug abuse and opioid use disorder crisis through enhanced law enforcement by making use of the drug a Schedule I crime under the Controlled Substances Act.
JUNE 25, 2025
Closing the Gaps in the Drug Supply Chain Security Act
With final Drug Supply Chain Security Act exemption dates ending this year for most stakeholders, the pharmaceutical supply chain is approaching full regulatory implementation.
JUNE 20, 2025
The NOPAIN Act: A New Era for Nonopioid Pain Management In Outpatient Surgery
With the implementation of the NOPAIN Act this past January, anesthesiologists and other perioperative care providers are entering a transformative period in pain management.
JUNE 17, 2025
FDA Approves Meloxicam Injection for Moderate to Severe Pain in Adults
The FDA has approved Xifyrm for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics.
JUNE 12, 2025
FDA Issues Refuse-to-File Letter for Experimental Fibromyalgia Drug
The FDA has sent a Refuse-to-File letter to Axsome Therapeutics in response to its new drug application for AXS-14, or esreboxetine, for the management of fibromyalgia.
JUNE 10, 2025